Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Sveafastigheter
Mandate

Vinge has advised Sveafastigheter

March 10, 2011

Vinge has advised Sveafastigheter in connection with the third and final closing of  Sveafastigheter Fund III which occurred on 28 February 2011. Including previous commitments, the fund has now secured capital commitments totaling EUR 317 million. The participants in the final closing were mainly leading global institutional investors.

Sveafastigheter Fund III will focus on real estate investments in the Nordic and Baltic countries, primarily Sweden and Finland.

Vinge’s team consisted of partners Pontus Enquist and Lennart Larsson and associate Johan Mattsson.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026